DSP-7888 Dosing Emulsion + Bevacizumab
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma
Trial Timeline
Dec 8, 2017 → Aug 30, 2021
NCT ID
NCT03149003About DSP-7888 Dosing Emulsion + Bevacizumab
DSP-7888 Dosing Emulsion + Bevacizumab is a phase 3 stage product being developed by Sumitomo Pharma for Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03149003. Target conditions include Glioblastoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03149003 | Phase 3 | Completed |
Competing Products
20 competing products in Glioblastoma